Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

Sleep Europe 2026 | Communicating α-synuclein seed amplification assay results to patients with iRBD

Gerard Maya, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses how α-synuclein seed amplification assay (SAA) results are communicated to patients with isolated REM sleep behavior disorder (iRBD), highlighting that testing is currently for research purposes only. Dr Maya explains that patients with a positive result are told their sleep disorder is very likely related to an α-synucleinopathy, with a risk of developing a disease in the Parkinson’s disease spectrum. If Alzheimer’s copathology is also present, he focuses on follow-ups every 6–12 months and early treatment of new symptoms. This interview took place at Sleep Europe 2026, which was held in Maastricht, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.